Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-03-27FDA Approved: QUETIAPINE FUMARATE — Original Application (Aurobindo Pharma Limited)
The FDA approved an original application for a generic quetiapine fumarate from Aurobindo Pharma Limited. This adds a generic option for the…
-
CLINICAL_TRIALS research · 2012-03-26Clinical Trial Update: Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia [NA]
An update on a trial investigating whether glucose mediates self-control performance in patients with schizophrenia; the trial status is unk…
-
CLINICAL_TRIALS research · 2012-03-23Clinical Trial Update: Minocycline Augmentation in Schizophrenia [NA]
A clinical trial is evaluating minocycline augmentation for schizophrenia. The current status is unknown.
-
FDA approval · 2012-03-22FDA Approved: ZIPRASIDONE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for ZIPRASIDONE submitted by Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS trial_result · 2012-03-20Clinical Trial Update: Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia [Phase 4]
A Phase 4 clinical trial evaluating histamine H2 antagonists as add-on therapy for treatment-resistant schizophrenia has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-03-20Clinical Trial Update: The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients [EARLY_Phase 1]
Early-phase clinical trial evaluating the effects of nicotine on arousal, cognition, and social cognition in individuals with schizophrenia;…
-
FDA approval · 2012-03-20FDA Approved: OLANZAPINE — Supplemental Application (American Regent, Inc.)
FDA approved a supplemental application for olanzapine from American Regent, Inc., for this generic product.
-
FDA approval · 2012-03-20FDA Approved: OLANZAPINE — Original Application (American Regent, Inc.)
FDA approves American Regent's original-application generic olanzapine product (olanzapine) for distribution in the United States.
-
FDA approval · 2012-03-12FDA Approved: RISPERIDONE — Supplemental Application (Janssen Pharmaceutical, Inc.)
FDA approved a supplemental application for risperidone (Risperidone) by Janssen Pharmaceutical, Inc. The approval signals changes or additi…
-
FDA label_change · 2012-03-12FDA Approved: RISPERDAL CONSTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for RISPERDAL CONSTA (risperidone) submitted by Janssen, likely resulting in labeling changes.
-
CLINICAL_TRIALS withdrawal · 2012-03-12Clinical Trial Update: Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation [NA]
A clinical trial investigating brain bioenergetics in bipolar disorder (and schizophrenia) in response to photic stimulation has been withdr…
-
CLINICAL_TRIALS trial_result · 2012-03-09Clinical Trial Update: Changes in Brain Synchronization During Perceptual and Linguistic Tasks in Schizophrenic Patients
This clinical trial report describes a study on brain synchronization during perceptual and linguistic tasks in individuals with schizophren…
-
CLINICAL_TRIALS trial_result · 2012-03-08Clinical Trial Update: Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia [Phase 2]
A Phase 2 trial evaluating the addition of sodium nitroprusside to treatment as usual in schizophrenia has completed, assessing the safety a…
-
CLINICAL_TRIALS trial_result · 2012-03-08Clinical Trial Update: Magnetoencephalographic (MEG) Evidence for Novel Metaphor Processing Among Schizophrenic Patients [NA]
A completed clinical trial evaluated magnetoencephalographic evidence for novel metaphor processing in patients with schizophrenia.
-
CLINICAL_TRIALS trial_result · 2012-03-07Clinical Trial Update: The Psychiatric Rehabilitation Approach to Weight Loss [NA]
This clinical trial update reports a completed study on a psychiatric rehabilitation approach to weight loss in schizophrenia.
-
CLINICAL_TRIALS research · 2012-03-07Clinical Trial Update: Cognitive Remediation in Early Phase Psychosis [NA]
An update on a cognitive remediation clinical trial in early-phase psychosis sponsored by Oslo University Hospital; the study covers schizop…
-
CLINICAL_TRIALS trial_result · 2012-03-05Clinical Trial Update: Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients [Phase 2]
Phase 2 clinical trial evaluating memantine as an adjunctive treatment for schizophrenia has completed, with emphasis on safety and efficacy…
-
FDA approval · 2012-03-02FDA Approved: ZIPRASIDONE HYDROCHLORIDE — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original application for a generic ziprasidone hydrochloride product, enabling a generic version of this antipsy…
-
FDA approval · 2012-03-02FDA Approved: ZIPRASIDONE — Original Application (Dr. Reddy's Laboratories Limited)
The FDA approved Dr. Reddy's Laboratories Limited's generic Ziprasidone as an original ANDA, enabling a generic version of the antipsychotic…
-
CLINICAL_TRIALS trial_result · 2012-03-02Clinical Trial Update: Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail [Phase 1, Phase 2]
Phase 1/2 pharmacological trial assessing social cognition, attentional networks, and nicotine dependence in individuals with tobacco use di…
-
FDA approval · 2012-03-01FDA Approved: RISPERIDONE — Supplemental Application (Westminster Pharmaceuticals, LLC)
The FDA granted Westminster Pharmaceuticals, LLC a supplemental approval for risperidone, updating the approved product's labeling.
-
CLINICAL_TRIALS trial_result · 2012-02-22Clinical Trial Update: A Study of Olanzapine in Patients With Schizophrenia [Phase 3]
Phase 3 clinical trial update assessing olanzapine in patients with schizophrenia; results were posted in 2012.
-
FDA approval · 2012-02-21FDA Approved: RISPERIDONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for risperidone from Sun Pharmaceutical Industries, Inc. under an Abbreviated New Drug Application, …
-
CLINICAL_TRIALS trial_result · 2012-02-20Clinical Trial Update: Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms [Phase 2]
Phase 2 trial update evaluating SPD489 in adults with schizophrenia and predominant negative symptoms; results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-02-20Clinical Trial Update: Artemisinin to Reduce The Symptoms of Schizophrenia [NA]
An update on a completed clinical trial evaluating artemisinin for reducing symptoms in schizophrenia and schizoaffective disorder; results …